Companies /Healthcare
West Pharmaceutical Services Inc
NYSE: WST Medical Instruments & Supplies

West Pharmaceutical Services (WST) Q3 2026 Earnings

Reported Oct 29, 2026, 7:06am ET · SEC source
$2.66
Beat +21.12%
EPS · est. $2.20 Adjusted

Adjusted EPS excludes a net $54.0 million pre-tax M&A benefit (mainly a $55.7 million gain on the SmartDose 3.5mL sale to AbbVie, with a $22.4 million one-time tax cost), $6.3 million of restructuring charges, $1.8 million of other nonrecurring professional fees (legal matters, May 2026 cybersecurity incident) and amortization; GAAP diluted EPS was $3.02

$874.5M
Beat +5.80%
Revenue · est. $826.5M
6 quarters
Consecutive EPS beats

How Did WST Stock React to Q3 2026 Earnings?

% change · around the report
0+3%+6%Oct 29Oct 30report 7:06am ETearnings−2.0%−0.1%
0+3%+6%Oct 29Oct 30earnings−2.0%−0.1%
WST −0.1%S&P 500 −2.0%
−4%0+4%Oct 29Oct 30report 7:06am ETearnings−4.1%−0.1%
−4%0+4%Oct 29Oct 30earnings−4.1%−0.1%
WST −0.1%NASDAQ −4.1%
−3%0+3%Oct 28Nov 3report 7:06am ETearnings−1.8%−3.1%
−3%0+3%Oct 28Nov 3earnings−1.8%−3.1%
WST −3.1%S&P 500 −1.8%
−3%0+3%Oct 28Nov 3report 7:06am ETearnings−4.0%−3.1%
−3%0+3%Oct 28Nov 3earnings−4.0%−3.1%
WST −3.1%NASDAQ −4.0%
+3.23%
Day of report
−0.97%
Next session
−5.81%
One week

Did WST Beat Earnings? Q3 2026 Results

Yes. West Pharmaceutical Services reported Q3 2026 earnings of $2.66 a share on Oct 29, 2026, beating the $2.20 consensus estimate by 21.1%. Revenue was $874.5M against a $826.5M estimate.

West Pharmaceutical Services delivered a standout third quarter of 2026, posting adjusted EPS of $2.66 against a consensus estimate of $2.20, a beat of 21.12% that extended the company's streak of exceeding consensus EPS estimates to five consecutive quarters. Revenue of $874.50 million rose 8.7% year over year and cleared the $826.55 million consensus by 5.80%, driven chiefly by a 20.3% organic surge in High-Value Product Components, which now account for 53% of total sales and benefited from broad demand across both GLP-1 and non-GLP-1 biologics. Gross margin expanded 310 basis points to 39.7%, while adjusted operating margin widened 420 basis points to 25.3%, underscoring the pricing and mix leverage embedded in the HVP portfolio. GAAP diluted EPS of $3.02 reflected a $55.70 million pre-tax gain from the completed SmartDose 3.5mL divestiture to AbbVie. With the strong quarter in hand, management raised full-year 2026 net sales guidance to $3.41 billion to $3.42 billion and lifted adjusted EPS guidance to $9.38 to $9.48, while also announcing an 18% dividend increase to $0.26 per share quarterly.

Key Takeaways
  • HVP Components net sales up 19.7% (20.3% organic), driven by volume, price and HVP conversion mix
  • Strong growth in both GLP-1 and non-GLP-1 products; GLP-1 elastomers were 12% and GLP-1 West Vantage revenues 9% of Q3 revenue
  • HVP conversions, including Annex 1 projects, generated over 200 bps of organic revenue growth
  • Biologics organic sales up 23.2%; Pharma organic sales up 21.4%
  • Asia Pacific organic sales up 41.9%
  • Gross margin up 310 bps to 39.7%; adjusted operating margin up 420 bps to 25.3%
  • $55.7 million pre-tax gain on the SmartDose 3.5mL sale boosted GAAP results
  • West Vantage margins improved sequentially after recovery from the Q2 cyber incident

“I am pleased to report strong third-quarter 2026 results, with net sales and adjusted EPS exceeding our expectations. Our results were again led by our High-Value Product (HVP) Components business. The robust sales performance drove strong operating income margin expansion and EPS growth. As a result of our team's strong execution in the third quarter, we are increasing our full-year 2026 guidance.”

West Pharmaceutical Services CEO, on the earnings call

What Is West Pharmaceutical Services's Outlook?

West raised its full-year 2026 guidance: - **Net sales:** $3.41 billion to $3.42 billion, up from $3.345–$3.380 billion. - **Organic growth:** 11.3% to 11.6%, up from 10%–11%. This excludes SmartDose 3.5mL sales; no further SmartDose 3.5mL sales are expected. - **Adjusted-diluted EPS:** $9.38 to $9.48, up from $8.85–$9.05. - **Reported-diluted EPS:** $9.31 to $9.41. - **Capital expenditures:** cut to $215 million–$220 million from $250 million–$275 million. - **Estimated tax rate:** approximately 18%. - **FX impact:** about +1.2% on full-year revenue and about +$0.10 on adjusted EPS. Fourth-quarter 2026 guidance: - **Revenue:** $820 million to $830 million, with organic growth of 6% to 7%. - **Adjusted EPS:** $2.22 to $2.32. - **FX impact:** about -0.9 points on revenue and about -$0.04 on EPS. - **Divestiture impact:** about -3.4 points on revenue.

WST YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$300.0M$600.0M$900.0M$804.3M$874.5MRevenue$293.5M$347.4MGross Profit$173.7M$267.4MOperating Income$140.0M$214.0MNet Income
$0$300.0M$600.0M$900.0MRevenueGross ProfitOperating IncomeNet Income
WST income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $874.5M $804.3M +8.7%
Gross Profit $347.4M $293.5M +18.4%
Operating Income $267.4M $173.7M +53.9%
Net Income $214.0M $140.0M +52.9%

WST Revenue by Segment

Proprietary Products$728.8M+12.6%
HVP Components$466.7M+19.7%
Biologics$379.3M+15.3%
Pharma$221.3M+21.3%
Standard Products$163.0M+2.9%
Contract-Manufactured Products
West Vantage$145.7M−7.3%
Generics$128.2M−5.7%

WST Revenue by Geography

Americas$401.3M+6.9%
EMEA$376.1M+4.2%
Asia Pacific$97.1M+42.4%

When Does West Pharmaceutical Services Report Next?

Expected report date
After the close
Release timing

Figures from SEC filings and company reports. Not investment advice.